Company · Private

YouthBio Therapeutics

Gene therapy company developing partial-reprogramming therapeutics based on Yamanaka-factor expression, led by YB002 for Alzheimer's disease.

Listing

Private

Ticker

—

Headquarters

Seattle, US

Founded

—

Technology

Partial reprogramming (Yamanaka factors), AAV delivery

Longevity thesis

Transient, controlled expression of reprogramming factors could restore youthful epigenetic state in diseased tissue without losing cell identity.

Programmes

YB002IND-enabling
Alzheimer's disease

Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.